Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Indication: Neoadjuvant Osimertinib with/without Chemo for NSCLC
Randomized, controlled, phase III study [NeoADAURA] NCT04351555 Resectable, EGFR-mutated, stage II-IIIB NSCLC Osimertinib+chemotherapy (n=121) vs Osimertinib (n=117) vs Placebo+che
New Protocol: Glofitamab with R-CHOP for High-Risk DLBCL
Phase II, open-label, multicenter study [COALITION; NCT04914741] Younger patients (≤65 years) with high-risk large B-cell lymphoma R-CHOP (n=40) vs Pola-R-CHP (n=40) with Glofi
New Protocol: Revumenib with Azacitidine and Venetoclax for KMT2-Rearranged / NPM1-Mutated
Phase I dose-escalation and expansion study [NCT03013998] First-line treatment for patients aged 60 years and older with newly diagnosed NPM1-mutated or KMT2A-rearranged AML Azac
New Reference: Pirtobrutinib for BTKi Pretreated CLL
Open-label, randomized, phase III study [BRUIN CLL-321] Relapsed/refractory CLL/SLL, previously treated with BTKi Pirtobrutinib (n=119) vs investigator's choice of Idelalisib/Ritux
New Reference: Nivolumab and Ipilimumab for Advanced Gastric Cancer
Single-arm phase II study [NO LIMIT, WJOG13320G]. Microsatellite instability-high advanced gastric or esophagogastric junction cancer. Nivolumab (240 mg every 2 weeks) plus low-dos
New Reference: Adagrasib for kRAS Mutated NSCLC
Randomised, open-label, phase 3 trial [KRYSTAL-12] Advanced NSCLC with KRASG12C mutation, previously treated with chemotherapy and immunotherapy 600 mg adagrasib twice daily (n=301
New Drug: Linvoseltamab for Relapsed/Refractory Myeloma
Phase I/II, first-in-human trial Relapsed/refractory multiple myeloma Livoseltamab 50mg (n=104) vs 200mg (n=117)
New Reference: Retifanlimab + Chemotherapy for Advanced Anal Cancer
Randomised, double-blind, phase 3 trial [POD1UM-303/InterAACT-2]. Patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal, aged >=18, ECO
New Indication: Periop Pembrolizumab for Head and Neck Cancer
Phase 3, open-label, randomized, multicenter trial [KEYNOTE-689] Locally advanced resectable head and neck squamous-cell carcinoma (HNSCC) Neoadjuvant and adjuvant pembrolizumab pl
